GlobalData on MSN1d
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment
Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...
ETF Daily News3d
Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 Shares of Stock
Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...
Viking Therapeutics’ Promising Phase 2 Trial and Competitive Edge Justify Buy Rating
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...